Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Strengthens Diabetes R&D With Option On Astellas/Prosidion's Early-Stage Compounds

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.

Advertisement

Related Content

AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
Astellas Pipeline Set For Patent Cliff Rebound
Astellas Considers Options To Shed All Or Parts Of Diabetes Unit Prosidion

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC077008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel